Literature DB >> 23211262

Multimorbidity, polypharmacy, referrals, and adverse drug events: are we doing things well?

Amaia Calderón-Larrañaga1, Beatriz Poblador-Plou, Francisca González-Rubio, Luis Andrés Gimeno-Feliu, José María Abad-Díez, Alexandra Prados-Torres.   

Abstract

BACKGROUND: The consequences of multimorbidity include polypharmacy and repeated referrals for specialised care, which may increase the risk of adverse drug events (ADEs). AIM: The objective of this study was to analyse the influence of multimorbidity, polypharmacy, and multiple referrals on the frequency of ADEs, as an indicator of therapeutic safety, in the context of a national healthcare system. DESIGN AND
SETTING: This was a multicentre, retrospective, observational study of 79 089 adult patients treated during 2008 in primary care centres.
METHOD: The explanatory patient variables sex, age, level of multimorbidity, polypharmacy, number of primary care physician visits, and number of different specialties attended were analysed. The response variable was the occurrence of ADEs. Logistic regression models were used to identify associations among the analysed variables.
RESULTS: The prevalence of individuals with at least one ADE was 0.88%. Multivariate analysis identified the following variables as risk factors for the occurrence of ADE in descending order of effect size: multimorbidity level (odds ratio [OR]Veryhigh/Low = 45.26; ORHigh/Low = 17.58; ORModerate/Low = 4.25), polypharmacy (OR = 1.34), female sex (OR = 1.31), number of different specialties (OR = 1.20), and number of primary care physician visits (OR = 1.01). Age, however, did not show statistical significance (OR = 1.00; 95% confidence interval = 0.996 to 1.005).
CONCLUSION: The results of this study demonstrate that multimorbidity is strongly related to the occurrence of ADEs, insofar as it requires the intervention of multiple specialties and the prescription of multiple medications. Further research should shed light on the causal pathway between multimorbidity and increased risk of adverse events.

Entities:  

Mesh:

Year:  2012        PMID: 23211262      PMCID: PMC3505415          DOI: 10.3399/bjgp12X659295

Source DB:  PubMed          Journal:  Br J Gen Pract        ISSN: 0960-1643            Impact factor:   5.386


  32 in total

1.  Adverse outpatient drug events--a problem and an opportunity.

Authors:  William M Tierney
Journal:  N Engl J Med       Date:  2003-04-17       Impact factor: 91.245

2.  Ambulatory care groups: a categorization of diagnoses for research and management.

Authors:  B Starfield; J Weiner; L Mumford; D Steinwachs
Journal:  Health Serv Res       Date:  1991-04       Impact factor: 3.402

3.  The European study of referrals from primary to secondary care. Concerned Action Committee of Health Services Research for the European Community.

Authors: 
Journal:  Occas Pap R Coll Gen Pract       Date:  1992-04

4.  Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies.

Authors:  J Lazarou; B H Pomeranz; P N Corey
Journal:  JAMA       Date:  1998-04-15       Impact factor: 56.272

5.  Drug-related morbidity and mortality. A cost-of-illness model.

Authors:  J A Johnson; J L Bootman
Journal:  Arch Intern Med       Date:  1995-10-09

6.  Risk factors for adverse drug events among older adults in the ambulatory setting.

Authors:  Terry S Field; Jerry H Gurwitz; Leslie R Harrold; Jeffrey Rothschild; Kristin R DeBellis; Andrew C Seger; Jill C Auger; Leslie A Garber; Cynthia Cadoret; Leslie S Fish; Lawrence D Garber; Michael Kelleher; David W Bates
Journal:  J Am Geriatr Soc       Date:  2004-08       Impact factor: 5.562

7.  Effects of geriatric evaluation and management on adverse drug reactions and suboptimal prescribing in the frail elderly.

Authors:  Kenneth E Schmader; Joseph T Hanlon; Carl F Pieper; Richard Sloane; Christine M Ruby; Jack Twersky; Susan Dove Francis; Laurence G Branch; Catherine I Lindblad; Margaret Artz; Morris Weinberger; John R Feussner; Harvey Jay Cohen
Journal:  Am J Med       Date:  2004-03-15       Impact factor: 4.965

Review 8.  Adverse drug reactions in elderly patients.

Authors:  P A Routledge; M S O'Mahony; K W Woodhouse
Journal:  Br J Clin Pharmacol       Date:  2004-02       Impact factor: 4.335

9.  Comorbidity: implications for the importance of primary care in 'case' management.

Authors:  Barbara Starfield; Klaus W Lemke; Terence Bernhardt; Steven S Foldes; Christopher B Forrest; Jonathan P Weiner
Journal:  Ann Fam Med       Date:  2003 May-Jun       Impact factor: 5.166

10.  Multimorbidity patterns in primary care: interactions among chronic diseases using factor analysis.

Authors:  Alexandra Prados-Torres; Beatriz Poblador-Plou; Amaia Calderón-Larrañaga; Luis Andrés Gimeno-Feliu; Francisca González-Rubio; Antonio Poncel-Falcó; Antoni Sicras-Mainar; José Tomás Alcalá-Nalvaiz
Journal:  PLoS One       Date:  2012-02-29       Impact factor: 3.240

View more
  72 in total

1.  GPs' management of polypharmacy and therapeutic dilemma in patients with multimorbidity: a cross-sectional survey of GPs in France.

Authors:  Hélène Carrier; Anna Zaytseva; Aurélie Bocquier; Patrick Villani; Hélène Verdoux; Martin Fortin; Pierre Verger
Journal:  Br J Gen Pract       Date:  2019-02-25       Impact factor: 5.386

2.  Charlson comorbidity index as a predictor of in-hospital death in acute ischemic stroke among very old patients: a single-cohort perspective study.

Authors:  Lorenzo Falsetti; Giovanna Viticchi; Nicola Tarquinio; Mauro Silvestrini; William Capeci; Vania Catozzo; Agnese Fioranelli; Laura Buratti; Francesco Pellegrini
Journal:  Neurol Sci       Date:  2016-05-11       Impact factor: 3.307

3.  Elderly patients' and GPs' perspectives of patient-GP communication concerning polypharmacy: a qualitative interview study.

Authors:  Andrea C Schöpf; Maike von Hirschhausen; Erik Farin; Andy Maun
Journal:  Prim Health Care Res Dev       Date:  2017-12-26       Impact factor: 1.458

4.  Prescribing for patients with multimorbidity: aiming to tailor to patient-set goals.

Authors:  Patricia Cahill
Journal:  Br J Gen Pract       Date:  2015-03       Impact factor: 5.386

5.  The Patient-Held Active Record of Medication Status (PHARMS) study: a mixed-methods feasibility analysis.

Authors:  Elaine K Walsh; Laura J Sahm; Colin P Bradley; Kieran Dalton; Kathleen O'Sullivan; Stephen McCarthy; Eimear Connolly; Ciara Fitzgerald; William H Smithson; David Kerins; Derina Byrne; Patricia M Kearney
Journal:  Br J Gen Pract       Date:  2019-05       Impact factor: 5.386

Review 6.  Health outcomes associated with polypharmacy in community-dwelling older adults: a systematic review.

Authors:  Terri R Fried; John O'Leary; Virginia Towle; Mary K Goldstein; Mark Trentalange; Deanna K Martin
Journal:  J Am Geriatr Soc       Date:  2014-12       Impact factor: 5.562

7.  Strategies to Improve Medication Adherence in Older Persons: Consensus Statement from the Senior Italia Federanziani Advisory Board.

Authors:  Alessandra Marengoni; Alessandro Monaco; Elisio Costa; Antonio Cherubini; Alexandra Prados-Torres; Christiane Muth; Renè J F Melis; Luca Pasina; Tischa J M van der Cammen; Katie Palmer; Sergio Pecorelli; Graziano Onder
Journal:  Drugs Aging       Date:  2016-09       Impact factor: 3.923

8.  Overuse and Misuse of Inhaled Corticosteroids Among Veterans with COPD: a Cross-sectional Study Evaluating Targets for De-implementation.

Authors:  Matthew F Griffith; Laura C Feemster; Steven B Zeliadt; Lucas M Donovan; Laura J Spece; Edmunds M Udris; David H Au
Journal:  J Gen Intern Med       Date:  2019-11-11       Impact factor: 5.128

Review 9.  Multi-drug therapy in chronic condition multimorbidity: a systematic review.

Authors:  Lucy Doos; Eyitope O Roberts; Nadia Corp; Umesh T Kadam
Journal:  Fam Pract       Date:  2014-09-05       Impact factor: 2.267

Review 10.  Aging and Multimorbidity: New Tasks, Priorities, and Frontiers for Integrated Gerontological and Clinical Research.

Authors:  Elisa Fabbri; Marco Zoli; Marta Gonzalez-Freire; Marcel E Salive; Stephanie A Studenski; Luigi Ferrucci
Journal:  J Am Med Dir Assoc       Date:  2015-05-07       Impact factor: 4.669

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.